Researchers at the Djavad Mowafaghian Centre for Brain Health, in collaboration with scientists at the Chongqing Medical University in Chongqing, China, recently discovered a way to slow the deterioration of memory. These findings significantly advance our understanding of the mechanism by which memory in our brain decays, and are the first to establish an opportunity for intervention to slow the progression of Alzheimer’s disease (AD) and related dementias.
For media enquiries or to connect with researchers in the MacVicar Lab at the Djavad Mowafaghian Centre for Brain Health, please contact Emily Wight, Communications Manager.
- Email: firstname.lastname@example.org
- Phone: 604-417-0165
For general enquiries about MacVicar Lab activities, please contact Katherine Rhodes at email@example.com.
Dr. Adele Diamond speaks to the power of executive function and its impact on student learning in this TEDxWestVancouverEd talk.
Collaborative International Research in Clinical and Longitudinal Experience for NMO Studies
In North America, Neuromyelitis Optica (NMO) affects four in 100,000 people, and can cause loss of vision in one or both eyes (optic neuritis) and numbness and weakness in the arms and legs (transverse myelitis). It is an unpredictable and chronic illness that is often confused with Multiple Sclerosis, but NMO is a distinct disease requiring different treatment.
Young athletes who experience concussions may need to wait longer than currently recommended before getting ‘back in the game’ because of the unique brain developmental stage of adolescence, according to new research. The study, published in the Journal of Neurotrauma, shows that current adult-based standards for assessing the effects of concussions and length of time to recovery may be inadequate for adolescents.
Interferon beta (IFN-β) is a disease-modifying drug used to reduce the risk of a future relapse (attacks) in people with multiple sclerosis (MS) by modulating the immune system. And while IFN-β is considered safe, it does hold a small possibility of side effects, including liver injury. While 30 to 60 per cent of individuals with MS treated with IFN-β will experience elevations in their liver enzyme test results, these elevations are often transient and disappear even with continued IFN-β treatment.
Dr. Haakon Nygaard comes to the Djavad Mowafaghian Centre for Brain Health (DMCBH) from Yale University, where he completed his internship in Internal Medicine, Residency in Neurology, and a PhD in Investigative Medicine under the mentorship of Dr. Stephen Strittmatter. He joined the Yale faculty as an Assistant Professor in Neurology, and during this time he co-founded the first Alzheimer’s clinic at Yale, and was the founding director of the Yale Behavioral Neurology and Neuropsychiatry fellowship program. Dr.
For the better part of a century, the neurotransmitter dopamine has been understood as a key player in the brain’s reward-related processing. Djavad Mowafaghian Centre for Brain Health and Vancouver Coastal Health Research Institute researcher Dr. Stan Floresco has discovered more precisely that bursts and dips of dopamine activity in the brain guide the level of risk taken when making a choice.